Effects of COVID-19 on diabetes care among dutch diabetes outpatients.

Autor: Bak JCG; Department of Vascular Medicine, Amsterdam University Medical Centers, location AMC Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands.; Dutch Institute for Clinical Auditing, Leiden, the Netherlands., Serné EH; Department of Vascular Medicine, Amsterdam University Medical Centers, location AMC Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands., Groenwold RHH; Leiden University Medical Center, Leiden, the Netherlands., de Valk HW; University Medical Center Utrecht, Utrecht, the Netherlands., Kramer MHH; Department of Vascular Medicine, Amsterdam University Medical Centers, location AMC Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands., Nieuwdorp M; Department of Vascular Medicine, Amsterdam University Medical Centers, location AMC Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands., Verheugt CL; Department of Vascular Medicine, Amsterdam University Medical Centers, location AMC Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands. c.verheugt@amsterdamumc.nl.
Jazyk: angličtina
Zdroj: Diabetology & metabolic syndrome [Diabetol Metab Syndr] 2023 Oct 10; Vol. 15 (1), pp. 193. Date of Electronic Publication: 2023 Oct 10.
DOI: 10.1186/s13098-023-01169-9
Abstrakt: Aims: The COVID-19 pandemic impacted diabetes care by reducing diabetes outpatient visits and diabetes-related screening due to allocation of healthcare resources. Yet the impact of COVID-19 on diabetes outpatients has not been extensively evaluated. This study aimed to assess the effect of the COVID-19 pandemic on diagnostics and intermediate outcomes of outpatient diabetes care pre- and during COVID.
Methods: This observational cohort study included 8,442 diabetes patients in the Dutch Pediatric and Adult Registry of Diabetes (DPARD) visiting diabetes outpatient clinics in 2019 and 2021. A mixed-effects regression analysis was used to examine differences in target achievement of HbA1c, BMI, blood pressure, LDL-cholesterol, eGFR, and the difference in mean HbA1c between 2019 and 2020 among n = 1,426 outpatients who visited in both years. Analyses were adjusted for age, sex, and BMI.
Results: A 22.7% (21.6-23.8%, p < 0.001) decline in outpatient volume was observed during the pandemic (2020). BMI, lipid spectrum, kidney function, and HbA1c were assessed less frequently in 2020 than in 2019. In 2020, compared to 2019, the median HbA1c level increased by 2.2% (1.0 mmol/mol, p = 0.035) and the percentages of patients with known HbA1C meeting targets below 10, 8, 7% (86, 64, and 53 mmol/mol) decreased by 0.5%, 1.7% and 1.4%, respectively. Target blood pressure ≤ 130/80 mmHg was achieved more often in 2020 (15.0% versus 18.3%, p = 0.018), while HbA1c ≤ 86 mmol/mol was achieved less (89.3% versus 87.1%, p = 0.001), among diabetes outpatients seen in both 2019 and 2020. In patients visiting both years, HbA1c was 2.3% (1.9 mmol/l, 95% CI 1.2-2.5, p < 0.001) lower during the pandemic than in the prepandemic (2019).
Conclusions: The COVID pandemic was associated with a marked reduction in patient volume in diabetes outpatient care among five hospitals. Among patients who received outpatient care both before and during the pandemic period, HbA1c control and blood pressure control enhanced during the pandemic. Re-evaluation of current diabetes outpatient care organization is warranted to ensure optimal diabetes care in future times.
(© 2023. BioMed Central Ltd., part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje